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ow-Density Lipoprotein
eduction and Cancer
ot Definitive But Provocative*
nthony N. DeMaria, MD, MACC,
ri Ben-Yehuda, MD, FACC
an Diego, California
n this issue of the Journal, Alsleikh-Ali et al. (1) present
ata suggesting an inverse relationship between the absolute
evel of low-density lipoprotein cholesterol (LDL-C)
eached in randomized clinical trials (RCTs) of statins and
he incidence of cancer. As acknowledged by the authors,
nd emphasized in an accompanying editorial, the findings
re not definitive but rather are hypothesis generating and
equire further investigation. Nevertheless, they are certainly
rovocative, and have considerable potential to alter the
rescription of and compliance with drug therapy of proven
fficacy. Therefore, we thought it would be worthwhile to
eview the process taken and considerations in reaching a
ecision to publish this manuscript.
See pages 409 and 419
Alsleikh-Ali et al. (1) initially submitted an analysis that
xamined the relationship of the degree of LDL-C lowering
o liver toxicity and rhabdomyolysis in RCTs assessing
tatin therapy. The effect of drug dosage was also examined.
oth reviewers and editors believed that the subject was
mportant in light of recent evidence that intense LDL
eduction yields superior benefits to moderate lowering.
owever, the editors requested that the authors include
ancer in the analysis, since this was the other major side
ffect often feared from statin therapy. Upon complying
ith this request, the authors uncovered what was to them
and to us) the unexpected relation of LDL level achieved
nd incidence of cancer. Recognizing that their data were
ar from definitive, they sought advice from the editors, who
ecommended submission of the analysis in full.
From the onset of the review, it was clear that the data
ere imperfect. The authors themselves listed numerous
imitations, including the retrospective use of summary data,
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.u
From the Division of Cardiovascular Medicine, University of California, San Diego
edical Center, San Diego, California.he use of data from clinical trials rather than “real-world”
xperience, and the lack of standardization of adverse events
n individual trials. Except for the PROSPER (Prospective
tudy of Pravastatin in the Elderly at Risk) trial, no
ndividual statin trial showed an increase of cancer. More-
ver, the report excluded data from 4 large statin RCTs
PROVE-IT [Pravastatin or Atorvastatin Evaluation and
nfection Therapy], A to Z [Aggrastat to Zocor], TNT
Treating to New Targets], and IDEAL [Incremental De-
rease in Clinical Endpoints Through Aggressive Lipid Low-
ring]). The study analyzed the relationship between LDL-C
evels achieved and incident cancer rates and does not contain
ata to implicate statins themselves as the cause. Even if true,
he increased risk of cancer would apply only at very low levels
f LDL, and would be offset by the major benefits demon-
trated for statin therapy in numerous clinical studies. The
ardiovascular benefit translates into an overall mortality re-
uction in high-risk patients (30% and 13% decrease in
ll-cause mortality in the 4S [Scandinavian Simvastatin Sur-
ival Study Group] and Heart Protection study, respectively).
Given the above limitations, and the potential for misin-
erpretation of the data, many people would argue (and
everal associate editors did) that we had adequate grounds
o reject the manuscript. In fact, this paper provoked
pirited discussions at 3 of our weekly meetings, additional
eviews, and several revisions. It was acknowledged that the
isinterpretation by physicians, portrayal by the media, and
he response of patients to the findings could all result in
arm. However, in the final analysis, the consensus was that
hese findings could not be ignored, that they did indeed
arrant further investigation, and that they should be aired
n public.
Having decided to publish the paper, it was clear that we
hould do so in the most responsible way possible. We
nvited an editorial to put the findings in proper perspective.
a Rosa’s (2) recommendation that a systematic analysis of
CTs not included in this study be funded and performed
s right on target, and trials that treat patients to specific
DL-C goals, rather than compare 2 statin doses, are
eeded as well. We prepared this essay explaining our
ationale and process. Finally, we plan to be as cautious,
alanced, and responsible in discussing this material with
he lay media as possible.
In the 5 years that we have been stewards of the Journal,
o other manuscript has stimulated such intense scrutiny
nd discussion. Given the growing public angst regarding
he safety of prescription medications, all were concerned
hat the paper contained great potential both for harm and
ood. In the end, we agreed to publish the article with as
uch caution and perspective as possible. This decision was
olstered largely by great confidence in the ability of our
eaders to interpret the data accurately and to act on the
ndings appropriately. Until additional data are available,
e believe adherence to existing National Cholesterol Ed-
cation Program guidelines is appropriate, especially with
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Editorial Comment July 31, 2007:421–2egard to the recommendation that lower LDL-C goals to
pproximately 70 mg/dl apply only to high-risk patients.
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